Abstract
OBJECTIVE: Evaluate the multiple end-organ targets affected by intradermal testing (IDT)-based immunotherapy.
STUDY DESIGN AND SETTING: We conducted a retrospective medical record review of 139 patients, as well as a follow-up questionnaire in a university setting.
RESULTS: Statistically significant differences (t-tests, P < 0.05) were observed in the prevalence of symptoms after IDT-based immunotherapy for each category (ear, eye, nasal, and throat). When divided into treatment time groups, the reduction was less in the first group (0–6 months therapy), than the subsequent groups (6–24 months and >24 months). The reduction leveled off after 6 months of therapy, with no difference seen between the 6- to 24-month and >24-month groups.
CONCLUSIONS: IDT-based immunotherapy has a broad response on otolaryngic allergy symptoms that appears to be consistent over time.
SIGNIFICANCE: IDT-based immunotherapy is an effective form of treatment for allergy-induced diseases of the head and neck.
Get full access to this article
View all access options for this article.